OrphanCrow: And it was then that OPK, I believe pulled up stakes and moved to Russia.
As I noted before, it seems to me that rather it was a russian capitalist, Sergey Pugachev, under the umbrella of his NZ-based investment corporation OPK Trust Company, formed OPK Biotech and bought the assets and intellectual property of the defunct Biopure. Actually, on the legal papers of a lawsuit involving OPK Biotech, it is plainly stated that:
This case involves defendant OPK Biotech (“OPK”), a purchaser of a defunct bankrupt company, (Biopure), and its ongoing attempt to recoup its losses through abuse of the legal system. [...] Defendant OPK, at all times mentioned herein, is a registered Delaware Limited Liability Corporation, headquartered in Moscow, licensed in the Commonwealth of Massachusetts, with manufacturing facilities located in Cambridge Massachusetts. OPK’s principal place of business is located at 11 Hurley Street, Cambridge MA, 02141. OPK’s registered Manager is Alex Pugachev, his Registration Address is CT Corporation System, 155 Federal Street, Suite 700, Boston, MA 02110.
Alex Pugachev is probably a relative of russian investor Sergey Pugachev.
Incidentally, the lawsuit is in itself very interesting, because it reveals the fraudulent practices of the inventors of Hemopure. The lawsuit was filed by a researcher, Dr. Abdel-Aleem, who was once hired by OPK Biotech to work on the development of Hemopure.
"On July 28, 2006, Abdel-Aleem’s employment with Biopure was terminated. Dr. Abdel- Aleem left Biopure because he had fundamental differences with the then CEO of Biopure, Zafiris Zaferilis, regarding the safety and reliability of Biopure’s product. In Dr. Abdel-Aleem’s professional opinion, based on published scientific studies, Biopure’s blood substitute product was unsafe for human use. Dr. Abdel-Aleem was unwilling to compromise his moral and ethical obligations to the public and Biopure’s shareholders by deceiving them into believing that Biopure’s product, Hemopure, was viable at the time. Hemopure never gained U.K. or U.S. regulatory approval. Dr. Abdel-Aleem feared that Biopure was attempting to abuse his credentials and reputation in the field of clinical trials to deceive shareholders."
Attempting to abuse someone's scientific credentials and reputation to deceive its members? Smells a lot like something the Watchtower Society is very accustomed to do.
Eden